WHO ICTRP trial
An open-label, single-arm, prospective study of TACE combined with apatinib for…
ChiCTR-OPN-17013220 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR-OPN-17013220 |
|---|---|
| Public title | An open-label, single-arm, prospective study of TACE combined with apatinib for unresectable liver metastases from colorectal cancer |
| Scientific title | An open-label, single-arm, prospective study of TACE combined with apatinib for unresectable liver metastases from colorectal cancer |
| Primary sponsor | Yueyang Hospital of integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Mesdicne |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Observational study |
| Phase | Post-market |
| Countries | China;China;China;China;China |
| Conditions | colorectal liver metastases |
| Interventions | Treatment group:TACE combined with apatinib |
| Registration date | Nov 2, 2017 |
| Target size | Treatment group:20 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: